TScan Therapeutics (TCRX) Competitors $1.75 -0.10 (-5.41%) Closing price 03:59 PM EasternExtended Trading$1.77 +0.02 (+0.91%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRX vs. INBX, AUTL, KMDA, AURA, YMAB, VIGL, AQST, OLMA, RCKT, and FULCShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Inhibrx Biosciences (INBX), Autolus Therapeutics (AUTL), Kamada (KMDA), Aura Biosciences (AURA), Y-mAbs Therapeutics (YMAB), Vigil Neuroscience (VIGL), Aquestive Therapeutics (AQST), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. Its Competitors Inhibrx Biosciences Autolus Therapeutics Kamada Aura Biosciences Y-mAbs Therapeutics Vigil Neuroscience Aquestive Therapeutics Olema Pharmaceuticals Rocket Pharmaceuticals Fulcrum Therapeutics Inhibrx Biosciences (NASDAQ:INBX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings. Which has stronger valuation and earnings, INBX or TCRX? Inhibrx Biosciences has higher earnings, but lower revenue than TScan Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx Biosciences$200K1,989.48$1.69B-$10.58-2.60TScan Therapeutics$2.82M35.22-$127.50M-$1.09-1.61 Does the media favor INBX or TCRX? In the previous week, Inhibrx Biosciences had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 4 mentions for Inhibrx Biosciences and 3 mentions for TScan Therapeutics. TScan Therapeutics' average media sentiment score of 1.77 beat Inhibrx Biosciences' score of 1.68 indicating that TScan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive TScan Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, INBX or TCRX? Inhibrx Biosciences has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500. Is INBX or TCRX more profitable? Inhibrx Biosciences has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,964.88%. TScan Therapeutics' return on equity of -63.33% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Inhibrx BiosciencesN/A -137.83% -76.31% TScan Therapeutics -1,964.88%-63.33%-40.19% Do insiders & institutionals hold more shares of INBX or TCRX? 82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 17.1% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 4.4% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer INBX or TCRX? TScan Therapeutics has a consensus target price of $7.80, suggesting a potential upside of 345.71%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTScan Therapeutics beats Inhibrx Biosciences on 11 of the 16 factors compared between the two stocks. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.31M$3.14B$5.81B$10.16BDividend YieldN/A2.32%5.69%4.60%P/E Ratio-1.6121.3674.6225.97Price / Sales35.22257.18454.4485.61Price / CashN/A45.3337.0859.91Price / Book0.419.6112.156.29Net Income-$127.50M-$53.29M$3.28B$270.77M7 Day Performance-8.38%0.36%0.98%3.32%1 Month Performance4.79%8.98%7.19%6.40%1 Year Performance-68.41%13.18%63.14%28.24% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics3.4105 of 5 stars$1.75-5.4%$7.80+345.7%-67.5%$99.31M$2.82M-1.61100Positive NewsINBXInhibrx Biosciences1.3009 of 5 stars$28.20+1.1%N/A+89.7%$408.49M$200K-2.67166News CoveragePositive NewsAUTLAutolus Therapeutics3.8465 of 5 stars$1.50-4.5%$9.12+508.0%-65.0%$399.21M$10.12M-1.79330Positive NewsShort Interest ↓KMDAKamada4.5505 of 5 stars$6.92-1.4%$13.00+87.9%+33.3%$397.93M$160.95M20.35360Positive NewsShort Interest ↓AURAAura Biosciences2.2575 of 5 stars$6.26-2.6%$22.00+251.4%-26.8%$388.87MN/A-3.1950Positive NewsYMABY-mAbs Therapeutics2.0783 of 5 stars$8.55+0.1%$9.62+12.5%-35.3%$388.50M$87.68M-17.10150News CoveragePositive NewsVIGLVigil NeuroscienceN/A$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340AQSTAquestive Therapeutics2.254 of 5 stars$3.77-1.6%$10.14+169.0%+0.0%$375.96M$57.56M-5.39160OLMAOlema Pharmaceuticals2.8747 of 5 stars$5.46-1.1%$24.00+339.6%-35.2%$374.74MN/A-2.7670News CoveragePositive NewsAnalyst UpgradeGap UpRCKTRocket Pharmaceuticals4.7945 of 5 stars$3.28-2.1%$16.73+410.2%-82.8%$353.92MN/A-1.31240Short Interest ↑FULCFulcrum Therapeutics2.6564 of 5 stars$6.48-2.6%$7.57+16.8%-21.0%$350.51M$80M-5.31100Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Inhibrx Biosciences Competitors Autolus Therapeutics Competitors Kamada Competitors Aura Biosciences Competitors Y-mAbs Therapeutics Competitors Vigil Neuroscience Competitors Aquestive Therapeutics Competitors Olema Pharmaceuticals Competitors Rocket Pharmaceuticals Competitors Fulcrum Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
